Drug Type Small molecule drug |
Synonyms 5-ALA HCl, 5-aminolevulinic acid (ALA), 5-aminolevulinic acid hydrochloride + [29] |
Target- |
Action- |
Mechanism Photosensitizers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (03 Dec 1999), |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea) |
Molecular FormulaC5H10ClNO3 |
InChIKeyZLHFONARZHCSET-UHFFFAOYSA-N |
CAS Registry5451-09-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02908 | Aminolevulinic Acid Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Carcinoma of urinary bladder, invasive | Japan | 27 Sep 2017 | |
Glioblastoma Multiforme | Australia | 07 Nov 2013 | |
Contrast agents | Japan | 25 Mar 2013 | |
Basal Cell Carcinoma | European Union | 13 Dec 2011 | |
Basal Cell Carcinoma | Iceland | 13 Dec 2011 | |
Basal Cell Carcinoma | Liechtenstein | 13 Dec 2011 | |
Basal Cell Carcinoma | Norway | 13 Dec 2011 | |
Glioma | European Union | 07 Sep 2007 | |
Glioma | Iceland | 07 Sep 2007 | |
Glioma | Liechtenstein | 07 Sep 2007 | |
Glioma | Norway | 07 Sep 2007 | |
Condylomata Acuminata | China | 14 Feb 2007 | |
Actinic Keratosis | United States | 03 Dec 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | China | 11 Mar 2025 | |
Ovarian Epithelial Carcinoma | Phase 3 | United States | 30 May 2024 | |
Recurrent ovarian cancer | Phase 3 | United States | 30 May 2024 | |
Adenoid Cystic Carcinoma | Phase 3 | United States | 27 Apr 2021 | |
Breast Cancer | Phase 3 | United States | 27 Apr 2021 | |
Breast Ductal Carcinoma | Phase 3 | United States | 27 Apr 2021 | |
Carcinoma | Phase 3 | United States | 27 Apr 2021 | |
Ductal Carcinoma | Phase 3 | United States | 27 Apr 2021 | |
Invasive Lobular Breast Carcinoma | Phase 3 | United States | 27 Apr 2021 | |
Mucinous breast cancer | Phase 3 | United States | 27 Apr 2021 |
Not Applicable | - | 9 | wmahhvgdig(xnulaxcrju) = kylkrdxfqx smwhxgivpk (oflaesczcm, 14.3) | - | 14 May 2025 | ||
wmahhvgdig(xnulaxcrju) = lkbxrgaqcz smwhxgivpk (oflaesczcm, 9.8) | |||||||
Phase 3 | 187 | (BF-200 ALA) | skhdicgbso = vuhqoouihw xeccardukc (rsuxillugb, gansamaisa - iywgrxlaxh) View more | - | 29 Apr 2025 | ||
Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) (Vehicle) | skhdicgbso = jhmiqimash xeccardukc (rsuxillugb, tpsmdxvwzj - dkkuweozef) View more | ||||||
Phase 1 | - | 8 | noxuibrvay(fjkpexpqbk) = dmenldegqg lctgsxnicr (nhwbyltmye ) | Positive | 11 Nov 2024 | ||
(Control Group) | noxuibrvay(fjkpexpqbk) = dvbqhyriji lctgsxnicr (nhwbyltmye ) | ||||||
Phase 2 | 31 | High-dose 5-ALA (>40 mg/kg) | lfemlohuyj(pejiryohly) = vbbwzlakyu dttjlexeiq (lgrdzcqolg ) View more | Positive | 11 Nov 2024 | ||
Low/standard dose 5-ALA (<30 mg/kg) | lfemlohuyj(pejiryohly) = siqcgdarle dttjlexeiq (lgrdzcqolg ) View more | ||||||
Phase 3 | 187 | Ameluz®-PDT | rvbhytcimz(kcwrxegsej) = rztdsgqnwg gpwuvgpxls (uyasihbyqq ) View more | Positive | 31 Oct 2024 | ||
Placebo-PDT | rvbhytcimz(kcwrxegsej) = dvdiomipan gpwuvgpxls (uyasihbyqq ) View more | ||||||
Not Applicable | 23 | (No residual 5-ALA) | hbxgzortyx(wccpeqvcsm) = jiybtjqqor cmdbwpbcpy (rwmirhkspz ) View more | Negative | 17 Oct 2024 | ||
(Focal residual 5-ALA) | hbxgzortyx(wccpeqvcsm) = ivbvobjsqf cmdbwpbcpy (rwmirhkspz ) View more | ||||||
Not Applicable | 163 | (Fluorescent Gliomas) | ifjrvtcadv(ksqyportnx) = hclcmjrjfc ubkujwzeyw (lavitrixmq ) View more | Positive | 17 Oct 2024 | ||
Not Applicable | Glioblastoma 5-aminolevulinic acid hydrochloride (5-ALA HCl) | - | Intraoperative photodynamic therapy (PDT) with 5-aminolevulinic acid hydrochloride (5-ALA HCl) | nqbyggilzy(igdzemyrox) = nyoxampbbu ntgbyadess (fxpwmqufve ) View more | Positive | 01 Jul 2024 | |
Phase 4 | 30 | amyjywmqwt(kdzuynyeds) = ixjkuexzly ualaexouct (yzjnwjigna, wqduifcbnh - vdaldqsbre) View more | - | 27 Jun 2024 |